Session

Overview: Radiation therapy for prostate cancer (PC) has historically been delivered in small daily doses over multiple weeks. PC appears to have a unique sensitivity to higher doses per fraction, rendering it susceptible to abbreviated forms of treatment. Stereotactic body radiation therapy (SBRT) and brachytherapy (BT) are both radiation modalities that allow the precise delivery of ablative doses in only a few fractions. SBRT has the advantage to be non-invasive while BT delivers the optimal dose distribution with maximal sparing of the adjacent organs at risk. In this session, the evidence regarding the radiobiology, oncological outcomes, toxicity and dose/fractionation schemes of SBRT and BT will be addressed.